

## APC Anti-Human CD79B Antibody

<b>Catalog Number:</b>	111809, 111810
<b>Size:</b>	25 tests, 100 tests
<b>Target Name:</b>	CD76b, Igb, Ig-beta, B29
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---


<b>Clone:</b>	Polatuzumab
<b>Application:</b>	Flow Cytometry
<b>Reactivity:</b>	Human
<b>Format:</b>	APC
<b>Isotype:</b>	Human IgG1
<b>Antibody Type:</b>	Monoclonal
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
<b>Protein Concentration:</b>	Supplied at a lot-specific concentration.
<b>Storage&amp;Handling:</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
<b>Recommended Usage:</b>	For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. APC has an excitation max at 650 nm and an emission max at 660 nm.
<b>Excitation Laser:</b>	Red Laser (633 nm)
<b>Isotype Control:</b>	301213

### BACKGROUND INFORMATION

---

Human CD79B (Igβ, B29) is a 36–40 kDa type I transmembrane glycoprotein expressed on B cells. It forms a heterodimer with CD79A to constitute the B-cell receptor complex, mediating antigen-triggered signaling that regulates B-cell development and activation. Containing an extracellular Ig-like domain and a cytoplasmic ITAM, CD79B is essential for BCR signaling. Mutations cause agammaglobulinemia type 6, and it serves as a diagnostic marker and therapeutic target for B-cell lymphomas.

PRODUCT DATA



Human peripheral blood lymphocytes were stained with PB Anti-Human CD19 and APC Anti-Human CD79b Polatuzumab (left) or an isotype control (right).

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.